Pierre‐Yves Berclaz

2.1k total citations
30 papers, 1.6k citations indexed

About

Pierre‐Yves Berclaz is a scholar working on Pulmonary and Respiratory Medicine, Rheumatology and Immunology. According to data from OpenAlex, Pierre‐Yves Berclaz has authored 30 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 8 papers in Rheumatology and 8 papers in Immunology. Recurrent topics in Pierre‐Yves Berclaz's work include Rheumatoid Arthritis Research and Therapies (8 papers), Inhalation and Respiratory Drug Delivery (6 papers) and Neonatal Respiratory Health Research (6 papers). Pierre‐Yves Berclaz is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (8 papers), Inhalation and Respiratory Drug Delivery (6 papers) and Neonatal Respiratory Health Research (6 papers). Pierre‐Yves Berclaz collaborates with scholars based in United States, Japan and Switzerland. Pierre‐Yves Berclaz's co-authors include Bruce C. Trapnell, Mark C. Genovese, Jeffrey A. Whitsett, Yoko Shibata, Zsuzsanna K. Zsengellér, Kazuhisa Otake, Marie–Dominique Filippi, Olivier Bénichou, Maria Greenwald and Li Xie and has published in prestigious journals such as New England Journal of Medicine, Blood and The Journal of Immunology.

In The Last Decade

Pierre‐Yves Berclaz

30 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Pierre‐Yves Berclaz United States	18	633	392	378	243	187	30	1.6k
Christof Iking‐Konert Germany	23	811 1.3×	333 0.8×	531 1.4×	282 1.2×	176 0.9×	67	1.8k
Akira Sagawa Japan	17	539 0.9×	380 1.0×	630 1.7×	216 0.9×	121 0.6×	75	1.8k
Keiko Yoshimoto Japan	24	946 1.5×	198 0.5×	555 1.5×	272 1.1×	111 0.6×	84	1.7k
Hirobumi Kondo Japan	25	404 0.6×	201 0.5×	516 1.4×	348 1.4×	137 0.7×	85	1.7k
Davit Manukyan Germany	10	723 1.1×	242 0.6×	256 0.7×	360 1.5×	470 2.5×	17	1.6k
Alain Chevailler France	26	841 1.3×	311 0.8×	269 0.7×	285 1.2×	204 1.1×	87	2.2k
Naoto Tamura Japan	23	884 1.4×	317 0.8×	1.0k 2.6×	327 1.3×	219 1.2×	196	2.2k
Mindy S. Lo United States	20	1.0k 1.6×	296 0.8×	775 2.1×	400 1.6×	194 1.0×	41	2.1k
Yair Molad Israel	25	725 1.1×	237 0.6×	959 2.5×	415 1.7×	220 1.2×	70	2.1k
William F. Pendergraft United States	25	758 1.2×	913 2.3×	413 1.1×	394 1.6×	66 0.4×	43	1.9k

Countries citing papers authored by Pierre‐Yves Berclaz

Since Specialization

Citations

This map shows the geographic impact of Pierre‐Yves Berclaz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pierre‐Yves Berclaz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pierre‐Yves Berclaz more than expected).

Fields of papers citing papers by Pierre‐Yves Berclaz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pierre‐Yves Berclaz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pierre‐Yves Berclaz. The network helps show where Pierre‐Yves Berclaz may publish in the future.

Co-authorship network of co-authors of Pierre‐Yves Berclaz

This figure shows the co-authorship network connecting the top 25 collaborators of Pierre‐Yves Berclaz. A scholar is included among the top collaborators of Pierre‐Yves Berclaz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pierre‐Yves Berclaz. Pierre‐Yves Berclaz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Genovese, Mark C., Gregg J. Silverman, Paul Emery, et al.. (2015). Efficacy and Safety of Tabalumab, an Anti–B-Cell–Activating Factor Monoclonal Antibody, in a Heterogeneous Rheumatoid Arthritis Population. JCR Journal of Clinical Rheumatology. 21(5). 231–238. 7 indexed citations

Genovese, Mark C., Daniel Braun, J. Erickson, et al.. (2015). Safety and Efficacy of Open-label Subcutaneous Ixekizumab Treatment for 48 Weeks in a Phase II Study in Biologic-naive and TNF-IR Patients with Rheumatoid Arthritis. The Journal of Rheumatology. 43(2). 289–297. 30 indexed citations

Krege, John H., David L. Kendler, Kelly Krohn, et al.. (2015). Relationship Between Vertebral Fracture Burden, Height Loss, and Pulmonary Function in Postmenopausal Women With Osteoporosis. Journal of Clinical Densitometry. 18(4). 506–511. 46 indexed citations

Genovese, Mark C., Maria Greenwald, Chul‐Soo Cho, et al.. (2014). A Phase II Randomized Study of Subcutaneous Ixekizumab, an Anti–Interleukin‐17 Monoclonal Antibody, in Rheumatoid Arthritis Patients Who Were Naive to Biologic Agents or Had an Inadequate Response to Tumor Necrosis Factor Inhibitors. Arthritis & Rheumatology. 66(7). 1693–1704. 174 indexed citations

Saeki, Hidehisa, Hidemi Nakagawa, Taeko Ishii, et al.. (2014). Efficacy and safety of open‐label ixekizumab treatment in Japanese patients with moderate‐to‐severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis. Journal of the European Academy of Dermatology and Venereology. 29(6). 1148–1155. 103 indexed citations

Greenwald, Maria, L Szczepański, A C Kennedy, et al.. (2014). A 52-week, open-label study evaluating the safety and efficacy of tabalumab, an anti-B-cell-activating factor monoclonal antibody, for rheumatoid arthritis. Arthritis Research & Therapy. 16(4). 415–415. 13 indexed citations

Keystone, Edward, Peter C. Taylor, Edit Drescher, et al.. (2014). Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. Annals of the Rheumatic Diseases. 74(2). 333–340. 225 indexed citations

Genovese, Mark C., Eric Lee, Julie Satterwhite, et al.. (2013). A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate. Annals of the Rheumatic Diseases. 72(9). 1453–1460. 41 indexed citations

Genovese, Mark C., Roy Fleischmann, Maria Greenwald, et al.. (2012). Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors. Annals of the Rheumatic Diseases. 72(9). 1461–1468. 56 indexed citations

10.

Jensen, Robert L., et al.. (2009). Quality control ofD_L,COinstruments in global clinical trials. European Respiratory Journal. 33(4). 828–834. 13 indexed citations

11.

Heilmann, Cory R., et al.. (2009). Safety and Efficacy of AIR Inhaled Insulin Compared with Subcutaneous Insulin in Patients Having Diabetes and Asthma: A 12-Month, Randomized, Noninferiority Trial. Diabetes Technology & Therapeutics. 11(s2). S–35. 6 indexed citations

12.

Wolzt, Michael, et al.. (2008). AIR Inhaled Insulin Versus Subcutaneous Insulin. Diabetes Care. 31(4). 735–740. 16 indexed citations

13.

Berclaz, Pierre‐Yves, Haitao Gao, Janet Tobian, et al.. (2008). The impact of diabetes and age on pulmonary function: Data from the National Health and Nutrition Examination Survey. Diabetes Research and Clinical Practice. 83(1). e1–e3. 2 indexed citations

14.

Uchida, Kanji, David Beck, Takashi Yamamoto, et al.. (2007). GM-CSF Autoantibodies and Neutrophil Dysfunction in Pulmonary Alveolar Proteinosis. New England Journal of Medicine. 356(6). 567–579. 200 indexed citations

15.

Berclaz, Pierre‐Yves, Brenna Carey, Kara Wernke-Dollries, et al.. (2006). GM-CSF Regulates a PU.1-Dependent Transcriptional Program Determining the Pulmonary Response to LPS. American Journal of Respiratory Cell and Molecular Biology. 36(1). 114–121. 66 indexed citations

16.

Standaert, T. A., Louis J Boitano, Julia Emerson, et al.. (2004). Standardized procedure for measurement of nasal potential difference: An outcome measure in multicenter cystic fibrosis clinical trials. Pediatric Pulmonology. 37(5). 385–392. 72 indexed citations

17.

Berclaz, Pierre‐Yves, Zsuzsanna K. Zsengellér, Yoko Shibata, et al.. (2002). Endocytic Internalization of Adenovirus, Nonspecific Phagocytosis, and Cytoskeletal Organization Are Coordinately Regulated in Alveolar Macrophages by GM-CSF and PU.1. The Journal of Immunology. 169(11). 6332–6342. 51 indexed citations

18.

Berclaz, Pierre‐Yves, Yoko Shibata, Jeffrey A. Whitsett, & Bruce C. Trapnell. (2002). GM-CSF, via PU.1, regulates alveolar macrophage FcγR-mediated phagocytosis and the IL-18/IFN-γ–mediated molecular connection between innate and adaptive immunity in the lung. Blood. 100(12). 4193–4200. 107 indexed citations

19.

Spicher, Virginie Masserey, Pierre‐Yves Berclaz, Jean‐Jacques Cheseaux, et al.. (2000). Detection of Enteroviruses in the Cerebrospinal Fluid by Polymerase Chain Reaction: Prospective Study of Impact on the Management of Hospitalized Children. Clinical Pediatrics. 39(4). 203–208. 24 indexed citations

20.

Berclaz, Pierre‐Yves, et al.. (1996). Changes in Protein Turnover and Resting Energy Expenditure after Treatment of Malaria in Gambian Children. Pediatric Research. 39(3). 401–409. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact